Literature DB >> 17409276

Crucial role of Rho-nuclear factor-kappaB axis in angiotensin II-induced renal injury.

Yuri Ozawa1, Hiroyuki Kobori.   

Abstract

This study was performed to determine the effectiveness of the Rho kinase inhibitor and NF-kappaB inhibitor in renal injury of ANG II-infused hypertensive rats. Male Sprague-Dawley rats, maintained on a normal diet, received either a sham operation (n = 7) or continuous ANG II infusion (120 ng/min) subcutaneously via minipumps. The ANG II-infused rats were further subdivided into three subgroups (n = 7 each) to receive one of the following treatments during the entire period: vehicle, Rho kinase inhibitor (fasudil; 3 mg.kg(-1).day(-1) ip), or NF-kappaB inhibitor (parthenolide; 1 mg.kg(-1).day(-1) ip). After 12 days of ANG II infusion, systolic blood pressure (BP; 208 +/- 7 vs. 136 +/- 3 mmHg), Rho kinase activity, NF-kappaB activity, renal ANG II contents (160 +/- 25 vs. 84 +/- 14 pg/g), monocytic chemotactic protein (MCP) 1 mRNA, interstitial macrophage infiltration, transforming growth factor-beta1 (TGF-beta1) mRNA, interstitial collagen-positive area, urinary protein excretion (43 +/- 6 vs. 11 +/- 2 mg/day), and urinary albumin excretion were significantly enhanced compared with the Sham group. While fasudil or parthenolide did not alter systolic BP (222 +/- and 190 +/- 21, respectively), both treatments completely blocked ANG II-induced enhancement of NF-kappaB activity, renal ANG II contents (103 +/- 11 and 116 +/- 21 pg/g, respectively), MCP1 mRNA, interstitial macrophage infiltration, TGF-beta1 mRNA, interstitial collagen-positive area, urinary protein excretion (28 +/- 6 and 23 +/- 3 mg/day, respectively), and urinary albumin excretion. Importantly, parthenolide did not alter ANG II-induced Rho kinase activation although fasudil abolished ANG II-induced Rho kinase activation. These data indicate that the Rho-NF-kappaB axis plays crucial roles in the development of ANG II-induced renal injury independently from BP regulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17409276      PMCID: PMC2094126          DOI: 10.1152/ajprenal.00520.2006

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  81 in total

1.  Rac GTPase instructs nuclear factor-kappaB activation by conveying the SCF complex and IkBalpha to the ruffling membranes.

Authors:  Laurent Boyer; Sara Travaglione; Loredana Falzano; Nils C Gauthier; Michel R Popoff; Emmanuel Lemichez; Carla Fiorentini; Alessia Fabbri
Journal:  Mol Biol Cell       Date:  2003-12-10       Impact factor: 4.138

2.  Vessel- and vasoconstrictor-dependent role of rho/rho-kinase in renal microvascular tone.

Authors:  Akira Nakamura; Koichi Hayashi; Yuri Ozawa; Keiji Fujiwara; Ken Okubo; Takeshi Kanda; Shu Wakino; Takao Saruta
Journal:  J Vasc Res       Date:  2003 May-Jun       Impact factor: 1.934

3.  Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase.

Authors:  M Amano; K Chihara; K Kimura; Y Fukata; N Nakamura; Y Matsuura; K Kaibuchi
Journal:  Science       Date:  1997-02-28       Impact factor: 47.728

4.  Chronic inhibition of nuclear factor-kappaB attenuates renal injury in the 5/6 renal ablation model.

Authors:  Clarice K Fujihara; Gláucia R Antunes; Ana L Mattar; Denise M A C Malheiros; José M Vieira; Roberto Zatz
Journal:  Am J Physiol Renal Physiol       Date:  2006-08-08

5.  C6 mediates chronic progression of tubulointerstitial damage in rats with remnant kidneys.

Authors:  Masaomi Nangaku; Jeffrey Pippin; William G Couser
Journal:  J Am Soc Nephrol       Date:  2002-04       Impact factor: 10.121

6.  Inhibition of nuclear factor-kappaB activation attenuates tubulointerstitial nephritis induced by gentamicin.

Authors:  Rildo A Volpini; Roberto S Costa; Cleonice G A da Silva; Terezila M Coimbra
Journal:  Nephron Physiol       Date:  2004

7.  Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.

Authors:  Yukiko Nagai; Li Yao; Hiroyuki Kobori; Kayoko Miyata; Yuri Ozawa; Akira Miyatake; Tokihito Yukimura; Takatomi Shokoji; Shoji Kimura; Hideyasu Kiyomoto; Masakazu Kohno; Youichi Abe; Akira Nishiyama
Journal:  J Am Soc Nephrol       Date:  2005-01-12       Impact factor: 10.121

8.  Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion.

Authors:  Jennelle C Hodge; Jeffrey Bub; Sushma Kaul; André Kajdacsy-Balla; Paul F Lindholm
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

9.  Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy.

Authors:  T Yamamoto; T Nakamura; N A Noble; E Ruoslahti; W A Border
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

10.  Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.

Authors:  D E Vaughan; S A Lazos; K Tong
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more
  27 in total

1.  Rho-kinase/nuclear factor-κβ/angiotensinogen axis in angiotensin II-induced renal injury.

Authors:  Hiroyuki Kobori; Yuri Ozawa; Omar W Acres; Kayoko Miyata; Ryousuke Satou
Journal:  Hypertens Res       Date:  2011-06-02       Impact factor: 3.872

Review 2.  Evidence for a functional intracellular angiotensin system in the proximal tubule of the kidney.

Authors:  Brianne Ellis; Xiao C Li; Elisa Miguel-Qin; Victor Gu; Jia L Zhuo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

Review 3.  The role of Rho protein signaling in hypertension.

Authors:  Gervaise Loirand; Pierre Pacaud
Journal:  Nat Rev Cardiol       Date:  2010-08-31       Impact factor: 32.419

4.  Fibroblast expression of an IκB dominant-negative transgene attenuates renal fibrosis.

Authors:  Tsutomu Inoue; Tsuneo Takenaka; Matsuhiko Hayashi; Toshiaki Monkawa; Jun Yoshino; Kouji Shimoda; Eric G Neilson; Hiromichi Suzuki; Hirokazu Okada
Journal:  J Am Soc Nephrol       Date:  2010-09-16       Impact factor: 10.121

5.  Contribution of a nuclear factor-kappaB binding site to human angiotensinogen promoter activity in renal proximal tubular cells.

Authors:  Omar W Acres; Ryousuke Satou; L Gabriel Navar; Hiroyuki Kobori
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

6.  ROCK/NF-κB axis-dependent augmentation of angiotensinogen by angiotensin II in primary-cultured preglomerular vascular smooth muscle cells.

Authors:  Kayoko Miyata; Ryousuke Satou; Weijian Shao; Minolfa C Prieto; Maki Urushihara; Hiroyuki Kobori; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2014-01-15

7.  Increased angiotensinogen expression, urinary angiotensinogen excretion, and tissue injury in nonclipped kidneys of two-kidney, one-clip hypertensive rats.

Authors:  Weijian Shao; Kayoko Miyata; Akemi Katsurada; Ryousuke Satou; Dale M Seth; Carla B Rosales; Minolfa C Prieto; Kenneth D Mitchell; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-18

8.  Determination of plasma and urinary angiotensinogen levels in rodents by newly developed ELISA.

Authors:  Hiroyuki Kobori; Akemi Katsurada; Kayoko Miyata; Naro Ohashi; Ryousuke Satou; Toshie Saito; Yoshiaki Hagiwara; Kazuya Miyashita; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2008-03-19

9.  Cardiac-specific suppression of NF-κB signaling prevents diabetic cardiomyopathy via inhibition of the renin-angiotensin system.

Authors:  Candice M Thomas; Qian Chen Yong; Rodolfo M Rosa; Rachid Seqqat; Shanthi Gopal; Dulce E Casarini; W Keith Jones; Sudhiranjan Gupta; Kenneth M Baker; Rajesh Kumar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-08-01       Impact factor: 4.733

Review 10.  Nuclear factor-kappaB as a hormonal intracellular signaling molecule: focus on angiotensin II-induced cardiovascular and renal injury.

Authors:  Xiao C Li; Jia L Zhuo
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-01       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.